

**IGHG3 Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP11218c****Specification**

---

**IGHG3 Antibody (Center) Blocking peptide -  
Product Information**

Primary Accession [P01860](#)  
Other Accession [CAA27268](#)

**IGHG3 Antibody (Center) Blocking peptide -  
Additional Information****Other Names**

Ig gamma-3 chain C region, HDC, Heavy  
chain disease protein, IGHG3

**Format**

Peptides are lyophilized in a solid powder  
format. Peptides can be reconstituted in  
solution using the appropriate buffer as  
needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6  
months. For long term storage store at  
-20°C.

**Precautions**

This product is for research use only. Not  
for use in diagnostic or therapeutic  
procedures.

**IGHG3 Antibody (Center) Blocking peptide -  
Protein Information****Name** IGHG3

{ECO:0000303|PubMed:11340299,  
ECO:0000303|Ref.9}

**Function**

Constant region of immunoglobulin heavy  
chains. Immunoglobulins, also known as  
antibodies, are membrane-bound or  
secreted glycoproteins produced by B  
lymphocytes. In the recognition phase of  
humoral immunity, the membrane-bound  
immunoglobulins serve as receptors which,  
upon binding of a specific antigen, trigger  
the clonal expansion and differentiation of B

lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:<a href="http://www.uniprot.org/citations/22158414" target="\_blank">22158414</a>, PubMed:<a href="http://www.uniprot.org/citations/20176268" target="\_blank">20176268</a>). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:<a href="http://www.uniprot.org/citations/17576170" target="\_blank">17576170</a>, PubMed:<a href="http://www.uniprot.org/citations/20176268" target="\_blank">20176268</a>).

**Cellular Location**

Secreted. Cell membrane

**IGHG3 Antibody (Center) Blocking peptide  
- Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)